Literature DB >> 18838475

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method.

Ilaria Iacobucci1, Annalisa Lonetti, Daniela Cilloni, Francesca Messa, Anna Ferrari, Roberta Zuntini, Simona Ferrari, Emanuela Ottaviani, Francesca Arruga, Stefania Paolini, Cristina Papayannidis, Pier Paolo Piccaluga, Simona Soverini, Giuseppe Saglio, Fabrizio Pane, Anna Baruzzi, Marco Vignetti, Giorgio Berton, Antonella Vitale, Sabina Chiaretti, Markus Müschen, Robin Foà, Michele Baccarani, Giovanni Martinelli.   

Abstract

BACKGROUND: Ikaros is the prototypic member of a Kruppel-like zinc finger transcription factor subfamily that is required for normal hematopoietic cell differentiation and proliferation, particularly in the lymphoid lineages. Alternative splicing can generate multiple Ikaros isoforms that lack different numbers of exons and have different functions. Shorter isoforms, which lack the amino-terminal domain that mediates sequence-specific DNA binding, exert a dominant negative effect and inhibit the ability of longer heterodimer partners to bind DNA. DESIGN AND METHODS: In this study, we developed a high-throughput capillary electrophoresis sizing method to detect and quantify different Ikaros cDNA transcripts.
RESULTS: We demonstrated that Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressed high levels of the non-DNA-binding isoform Ik6 that was generated following IKZF1 genomic deletions (19/46 patients, 41%). Furthermore, a recurring 60 bp insertion immediately upstream of exon 5, at the exon 3/exon 5 junction, was frequently detected in the Ik2 and Ik4 isoforms. This insertion occurred either alone or together with an in-frame ten amino acid deletion that was due to a 30 bp loss at the end of exon 7. Both the alterations are due to the selection of alternative cryptic splice sites and have been suggested to cause impaired DNA-binding activity. Non-DNA-binding isoforms were localized in the cytoplasm whereas the DNA-binding isoforms were localized in the nucleus.
CONCLUSIONS: Our findings demonstrate that both aberrant splicing and genomic deletion leading to different non-DNA-binding Ikaros cDNA transcripts are common features of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838475     DOI: 10.3324/haematol.13260

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Emerging technologies in paediatric leukaemia.

Authors:  Amanda Dixon-McIver
Journal:  Transl Pediatr       Date:  2015-04

2.  Regulator of myeloid differentiation and function: The secret life of Ikaros.

Authors:  Olivia L Francis; Jonathon L Payne; Rui-Jun Su; Kimberly J Payne
Journal:  World J Biol Chem       Date:  2011-06-26

3.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

4.  Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

Authors:  M Kim; J Park; D-W Kim; Y-J Kim; Y-W Jeon; J-H Yoon; S-H Shin; S-A Yahng; S-E Lee; B-S Cho; K-S Eom; H-J Kim; C-Ki Min; S-G Cho; Y Kim; J-W Lee; K Han; W-S Min; S Lee
Journal:  Bone Marrow Transplant       Date:  2014-12-15       Impact factor: 5.483

5.  Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.

Authors:  Yuya Sasaki; Hagop M Kantarjian; Nicholas J Short; Feng Wang; Ken Furudate; Hidetaka Uryu; Rebecca Garris; Nitin Jain; Koji Sasaki; Farhad Ravandi; Marina Konopleva; Guillermo Garcia-Manero; Latasha Little; Curtis Gumbs; Li Zhao; P Andrew Futreal; Koichi Takahashi; Elias Jabbour
Journal:  Leukemia       Date:  2022-02-07       Impact factor: 12.883

6.  Ikaros6 is associated with BCR-ABL1 and myeloid-associated antigens but indicates poor prognosis independently in Chinese adult B-cell acute lymphoblastic leukemia.

Authors:  Na Zhang; Chunrui Li; Danmei Xu; Yanan Liu; Xiaoyi Ding; Kefeng Shen; Jianfeng Zhou; Min Xiao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.

Authors:  Chunhua Song; Zheng Ge; Yali Ding; Bi-Hua Tan; Dhimant Desai; Krishne Gowda; Shantu Amin; Raghavendra Gowda; Gavin P Robertson; Feng Yue; Suming Huang; Vladimir Spiegelman; Jonathon L Payne; Mark E Reeves; Zafer Gurel; Soumya Iyer; Pavan Kumar Dhanyamraju; Meixian Xiang; Yuka Imamura Kawasawa; Nathalia M Cury; José Andrés Yunes; Mary McGrath; Joe Schramm; Ruijun Su; Yiping Yang; Zhijun Zhao; Xiaoguang Lyu; Markus Muschen; Kimberly J Payne; Chandrika Gowda; Sinisa Dovat
Journal:  Blood       Date:  2020-09-24       Impact factor: 22.113

8.  A novel, non-canonical splice variant of the Ikaros gene is aberrantly expressed in B-cell lymphoproliferative disorders.

Authors:  Daria Capece; Francesca Zazzeroni; Maria Michela Mancarelli; Daniela Verzella; Mariafausta Fischietti; Ambra Di Tommaso; Rita Maccarone; Sara Plebani; Mauro Di Ianni; Alberto Gulino; Edoardo Alesse
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  The combined expression patterns of Ikaros isoforms characterize different hematological tumor subtypes.

Authors:  Carlos A Orozco; Andrés Acevedo; Lazaro Cortina; Gina E Cuellar; Mónica Duarte; Liliana Martín; Néstor M Mesa; Javier Muñoz; Carlos A Portilla; Sandra M Quijano; Guillermo Quintero; Miriam Rodriguez; Carlos E Saavedra; Helena Groot; María M Torres; Valeriano López-Segura
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

10.  Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL.

Authors:  Xiaojing Lin; Xingli Zou; Ziming Wang; Qin Fang; Shuya Chen; Jun Huang; Nana Zhe; Meisheng Yu; Yaming Zhang; Jishi Wang
Journal:  Oncotarget       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.